Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 1 1

Status

Recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 4Other solid neoplasm 3Gastrointestinal 3Myeloid 2Dermatologic 2Tumor-Agnostic 1Other neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 4Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Infusions, Intravenous × Other hematologic neoplasm × Clear all
NCT03850574 2025-08-26

TUSCANY

Aptose Biosciences Inc.

Phase 1/2 Recruiting
240 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06232694 2024-01-31

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

The First Affiliated Hospital with Nanjing Medical University

Phase NA Recruiting
54 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05448599 2023-03-15

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Unknown
120 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05001451 2022-07-20

Study of GDX012 in Patients With MRD Positive AML

GammaDelta Therapeutics Limited

Phase 1 Terminated
3 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡